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BACKGROUND: Cyclooxygenase-2 (COX-2) overexpression is strongly associated with colorectal tumourigenesis. It has been
demonstrated that the chronic use of non-steroidal anti-inflammatory drugs (COX inhibitors) partially protects patients from
colorectal cancer (CRC) development and progression but induces severe cardiovascular side effects. New strategies for selective
COX-2 blockade are required.
METHODS: We developed an improved technique, based on RNA interference (RNAi), to gain a selective COX-2 silencing in CRC
cells by a tumour-dependent expression of anti-COX-2 short-hairpin RNA (shCOX-2). Anti-COX-2 shRNA-expressing vectors
were delivered in CRC cells (in vitro) and in colon tissues (ex vivo) using engineered Escherichia coli strains, capable of invading tumour
cells (InvColi).
RESULTS: A highly tumour-dependent shCOX-2 expression and a significant COX-2 silencing were observed in CRC cells following
InvColi strain infection. Cyclooxygenase-2 silencing was associated with a strong reduction in both proliferative and invasive behaviour
of tumour cells. We also demonstrated a pivotal role of COX-2 overexpression for the survival of CRC cells after bacterial infection.
Moreover, COX-2 silencing was achieved ex vivo by infecting colon tissue samples with InvColi strains, leading to anti-inflammatory
and anti-tumour effects.
CONCLUSION: Our RNAi/InvColi-mediated approach offers a promising tool for a highly selective COX-2 blockade in vitro and in vivo.
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Colorectal cancer (CRC) represents the third most common
tumour in humans and the second leading cause of tumour-
related death in Western countries. In Europe, 4400000 new
cases and 4200000 deaths per year are estimated (Ferlay et al,
2007). The mortality rate of CRC dramatically increases when
tumour cells invade the primary tissue and generate lymph nodal
and liver metastases. Owing to its high incidence and mortality
rate, CRC is of great interest for the scientific community.
Over the last few decades, it has been demonstrated that the
chronic use of non-steroidal anti-inflammatory drugs (NSAIDs),
blocking isoforms 1 and 2 of the cyclooxygenase (COX) enzyme,
confers a 40–50% reduction in the incidence of CRC (Phillips et al,
2002; Thun et al, 2002; Higuchi et al, 2003; Sandler et al, 2003).
Cyclooxygenase is a key enzyme in the metabolism of arachidonate
and regulates the synthesis of prostaglandins (H2, D2, E2, F2a, I2)
and tromboxanes (TXA2 and TXB2), both having important roles
as cellular mediators. Cyclooxygenase-2 represents the product of
the Cox-2 inducible gene. It is overexpressed in 40% of adenomas
and in 80% of adenocarcinomas (Eberhart et al, 1994; Sano et al,
1995), and such an overexpression has been strongly associated
with colon tumourigenesis both in vitro and in murine models
(DuBois et al, 1996; Oshima et al, 1996; Williams et al, 1996). It is
commonly accepted that COX-2 can contribute to CRC develop-
ment and progression through mechanisms involving the stimula-
tion of angiogenesis (Spisni and Tomasi, 1997; In ˜iguez et al, 2003),
the inhibition of apoptosis (Tsujii and DuBois, 1995) and the
increase in cell migration/invasiveness (Yamauchi et al, 2002;
Strillacci et al, 2006).
Celecoxib and rofecoxib were the first NSAIDs marketed as
selective COX-2 inhibitors and they have been used in clinical
trials to test their efficacy in the prevention and/or treatment
of CRC. Unfortunately, celecoxib and, particularly, rofecoxib
have been shown to significantly increase the risk of adverse
cardiovascular events and myocardial infarction in treated patients
(Bresalier et al, 2005; Solomon et al, 2005). Moreover, the
cardiovascular toxicity of rofecoxib could be increased by its
capability to directly inhibit prostacyclin synthase activity, as
demonstrated by our group (Griffoni et al, 2007). Although
celecoxib is still marketed, rofecoxib has been withdrawn from the
worldwide market by Merck in September 2004.
RNA interference (RNAi) has rapidly become an innovative and
elective tool for gene silencing at the post-transcriptional level.
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sRNAi-mediated gene silencing can be achieved using small
interfering RNA (siRNA) or short-hairpin RNA (shRNA) as
precursor molecules. Although synthetic siRNAs are introduced
in mammal cells using standard in vitro transfection methods,
shRNAs are expressed after transfecting cells with plasmids (Lewis
et al, 2002) or viral-based vectors (Brummelkamp et al, 2002).
Numerous advantages come from shRNA-based RNAi approach:
first, the possibility to obtain a long-term gene silencing; and
second, the possibility to express shRNAs in a spatial- and/or
temporal-specific manner using tissue-specific promoters or
introducing regulatory elements on shRNA promoters.
In 2006, our research group demonstrated that it is possible to
stably silence the COX-2 protein in a CRC cell line (HT-29) using
the anti-COX-2 shRNA (shCOX-2). HT-29
pS(shCOX 2) showed a
significant impairment of malignant behaviour (Strillacci et al,
2006) and a reduced ability to survive under hypoxic conditions
(Sansone et al, 2009). To date, RNAi approaches have been used to
efficiently silence the COX-2 protein in many different in vitro
models (for a review, see Strillacci et al, 2010).
Several years ago, it was demonstrated that a functional gene
transfer from bacteria to mammalian cells could occur.
In particular, engineered Escherichia coli, expressing Inv and
HlyA genes (from Yersinia pseudotuberculosis and Lysteria
monocytogenes, respectively), was found to be able to invade and
release DNA into host cells (Grillot-Courvalin et al, 1998). This
phenomenon was also demonstrated in vivo, as it was observed
that invasive E. coli can deliver therapeutic genes to the colonic
mucosa in mice (Castagliuolo et al, 2005). Similarly, a successful
transfer of shRNA into mammalian cells was achieved using non-
pathogenic E. coli transformed with a plasmid containing
expression cassettes for shRNA and Inv/HlyA genes. In 2006,
Xiang et al (2006) applied this new strategy for the first time
(termed ‘trans-kingdom RNAi’) to silence the b-1 catenin gene
(CTNNB1) in human cells both in vitro and in vivo.
In this paper, we describe an effective method by which shCOX-
2-expressing vectors can be delivered into CRC cells (in vitro) and
in COX-2-overexpressing colonic tissues (ex vivo), using invasive
E. coli strains to achieve a strong COX-2 silencing mediated by
RNAi, coupled to anti-tumour effects. This strategy may prove to
be suitable for an in vivo application aiming at COX-2 inhibition
and CRC prevention.
MATERIALS AND METHODS
Cell lines
Human cancer cell lines HCA-7, HT-29, HCT-116, HeLa and
human transformed kidney cell line HEK-293 were obtained
from the American Type Culture Collection (Manassas, VA, USA).
Normal human colon mucosal epithelial cell line NCM-460 (Moyer
et al, 1996) was obtained after a licensing agreement with INCELL
Corporation (San Antonio, TX, USA). Both HT-29
pS( ) and HT-
29
pS(shCOX 2) cells have been previously created by our group, as
described elsewhere (Strillacci et al, 2006). Cell lines were cultured
at 371Ci n5 %C O 2 in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated fetal calf serum
(FCS), 2mML -glutamine and kanamycin 100mgml
 1. Both FCS
and DMEM were purchased from Cambrex BioWhittaker (Charles
City, IA, USA). The NCM-460 cells were cultured in the M3 base
media obtained from INCELL Corporation. All other reagents were
purchased from Sigma (St Louis, MO, USA).
Colon tissue culture
Fresh colon biopsies were collected from patients affected by acute
ulcerative colitis during endoscopy and immediately cultured in
the MegaCell RPMI-1640 medium (Sigma). Patients gave written
informed consent to participate in the study, which was approved
by the local ethical committee.
Plasmids
The empty pSUPER.retro vector (pS
 ), based on the murine stem
cell virus (MSCV) genome, was purchased from Oligoengine
(Seattle, WA, USA). The pSUPER.retro vector expressing shCOX-2
under RNA pol III H1 promoter control (pS
H1) was created as
described elsewhere (Strillacci et al, 2006). pSUPER.retro vectors
expressing shCOX-2 under control of human Cox-2 promoter
(pS
COX 2) and TBE (Tcf-binding element)-based promoter (pS
TBE)
were created as follows: in both vectors, RNA pol III transcription
stop signal was substituted with a SV40 polyA sequence between
HindIII and SalI restriction sites (SV40 polyA sequence was
amplified from the hER/pSG5 expression plasmid; forward primer:
50-CCCAAGCTTAAATAAAGCAATAGCATCAC-30; reverse primer:
50-TAGAGTCGACCAGACATGATAAGAT-30, 120bp product); in
pS
COX 2, the H1 promoter (pH1) was substituted with the human
Cox-2 promoter sequence (pCOX-2) between ApaI and BglII
restriction sites (pCOX-2 sequence was amplified from HCA-7
genomic DNA; forward primer: 50-CGGGCCCTGAGCACTACCC
ATGATA-30; reverse primer: 50-GAAGATCTCCGAGAGAA
CCTTCC-30, 1254bp product); in pS
TBE, pH1 was substituted with
the TBE-based promoter sequence (pTBE) between ApaI and BglII
restriction sites (the pTBE sequence was amplified from TOP-
FLASH plasmid, kindly provided by Dr Hans Clevers, University
Hospital, Utrecht, The Netherlands; forward primer: 50-CG
GGCCCAAGCTATCAAAGGG-30; reverse primer: 50-CGAGAT
CTGGCGCCTCAGCTGGC-30, 151bp product). A comprehensive
scheme of pS vectors described above is shown in Figure 1.
Transfections
HCA-7, HT-29, HCT-116, NCM-460, HeLa and HEK-293 cells were
seeded in 6-well plates (B7 10
5 cells per well) at 70% confluence.
After 24h, cells were transfected with pS
 ,p S
H1,p S
COX 2 and
pS
TBE vectors using Lipofectamine 2000 transfection reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. After 6h of incubation at 371C, the transfection
medium was replaced with 2ml of complete medium containing
10% FCS. Cells were lysed 48h after transfection for real-time PCR
and western blot analyses.
RNA extraction and real-time PCR
Total RNA from cultured cells was extracted using Eurozol reagent
(Celbio, Milan, Italy) according to the manufacturer’s instructions.
Extracted RNA samples were treated with DNase I to remove any
genomic DNA contamination using DNA-free kit (Ambion, Austin,
TX, USA) and reverse transcribed using RevertAid First-Strand
cDNA Synthesis Kit (Fermentas, Burlington, Ontario, Canada).
Both COX-2 and b-glucuronidase (GUSB) mRNAs were reverse
transcribed using random hexamer primers (Fermentas). The
siCOX-2 was reverse transcribed using the stem-loop RT–PCR
technique (Chen et al, 2005) using the following primer: 50-G
TCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAC
AAATTCC-30. U6 RNA was reverse transcribed using the following
primer: 50-AAAATATGGAACGCTTCACG-30. Both COX-2 mRNA
and siCOX-2 levels were analysed by real-time PCR using SYBR
supermix (Bio-Rad, Hercules, CA, USA) and iCycler system (Bio-
Rad) according to the manufacturer’s instructions. The melting
curve data were collected to check PCR specificity. Each cDNA
sample was analysed in triplicate. Cyclooxygenase-2 mRNA levels
were normalised against GUSB mRNA, whereas siCOX-2 expres-
sion was normalised against U6 RNA levels. Relative expressions
were calculated using the formula 2
 2DCt values (DCt¼
Ctgene Cthk). Cyclooxygenase-2 primer pair: 50-CCTGTGCCTGAT
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sGATTGC-30 and 50-CTGATGCGTGAAGTGCTG-30 (165bp pro-
duct); siCOX-2 primer pair: 50-GCAACTGCTCAACACCG-30 and
50-TGCAGGGTCCGAGGTAT-30 (56bp product); GUSB primer
pair: 50-TGGTATAAGAAGTATCAGAAGCC-30 and 50-GTATC
TCTCTCGCAAAAGGAAC-30 (297bp product); U6 primer pair:
50-CTTCGGCAGCACATATACT-30 and 50-AAAATATGGAACG
CTTCACG-30 (99bp product).
InvColi strains and bacterial infection
The E. coli (DH5a strain) was co-transformed with the pGB2-O-
inv-hly plasmid (Sm
Rþ, kindly provided by Dr Catherine Grillot-
Courvalin, Institut Pasteur, Paris) and pSUPER.retro (Amp
Rþ)
vectors to obtain E. coli invasive strains carrying the three different
shCOX-2 expression vectors (namely InvColi-pS
H1, InvColi-
pS
COX 2 and InvColi-pS
TBE) and the negative control (InvColi-
pS
 ). Selection of co-transformed strains was based on both
streptomycin and ampicillin resistance. Both HT-29 and HCA-7
cell lines were infected with InvColi strains according to the
following procedure: cells were seeded in 25cm
2 flasks at 50%
confluence (B3 10
6 cells) in an antibiotic-free medium (DMEM);
InvColi strains were grown in LB medium at 371C to reach an
OD600 of B1.00; InvColi bacteria were then washed twice in fresh
LB medium, re-suspended in antibiotic-free DMEM and added to
cells’ media at an MOI (multiplicity of infection) of 1:1000; after 2h
of incubation at 371Ci n5 %C O 2, cells were washed and fresh
DMEM medium supplemented with kanamycin was added to the
flasks. Cells were lysed 48h after infection for western blot and
real-time PCR analyses. With regard to colon tissue samples,
infection was achieved immediately after endoscopic resection by
co-culturing biopsies and InvColi-pS strains in MegaCell RPMI-
1640 medium as described above. Biopsies were lysed and
supernatants were collected 48h after infection for western blot,
real-time PCR and Luminex (Luminex, Austin, TX, USA) analyses.
Western blot
Cultured cells were homogenised in lysis buffer (50mM Tris-HCl,
pH 7.5, 2mM EDTA, 100mM NaCl, 1% Triton X-100, protease
inhibitors mixture). Cell lysates were incubated 1h on ice and
centrifuged at 12000g to collect supernatants. After addition of
SDS–PAGE sample buffer and boiling, 40mg of denatured proteins
was separated in 12% SDS–PAGE and then transferred onto
nitrocellulose papers. After blotting, nitrocellulose papers were
incubated with specific antibodies. The primary antibodies used
were polyclonal anti-COX-2 (Cayman Chemicals, Ann Arbor, MI,
USA) and anti-b-actin (Sigma). Secondary antibodies (HRP
conjugated) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Immunolabelling was visualised using
the ECL procedure (Amersham Biosciences, Piscataway, NJ, USA).
Bands were quantified using densitometric image analysis software
(Quantity One, Bio-Rad). Normalisation was made against b-actin
expression.
Fluorescence and Inv-HlyA-pTBE sequence detection
InvColi pS
TBE-infected cells were analysed 48h after infection
using the Nikon Eclipse 90i microscope (Nikon, Tokyo, Japan) to
detect green fluorescent protein (GFP) expression. The total DNA
of infected cells was extracted using phenol/chloroform procedure
24h after infection, and the presence of pGB2-O-inv-hly and pS
TBE
plasmids was confirmed by standard PCR technique, followed by
agarose gel electrophoresis analysis. Inv primer pair: 50-GCCAA
TAAGGAGCAGGAGAC-30 and 50-CCAAGGAGCCAGCCAATC-30
(225bp product); HlyA primer pair: 50-CATTTCACATCGTC
CATCTATTTG-30 and 50-TTACCGTTCTCCACCATTCC-30 (100bp
product); pTBE sequence primer pair (see above). The PCR
analysis was also performed on E. coli co-transformed with pGB2-
O-inv-hly and pS
TBE plasmids (pre-heated at 951C for 5min) and
on purified plasmids themselves.
Cell proliferation and viability analysis
Both HT-29 and HCA-7 cells were infected with InvColi strains.
Twenty-four hours after infection (day 0), cells were seeded in
12-well plates (HT-29: 5 10
4 cells per well; HCA-7: 2 10
4 cells
per well). On days 1, 2, 3, 6 and 8, cells were trypsinised, re-
suspended in PBS 1  and incubated for 10min in 0.4% Trypan
Blue (Sigma). Cells were then counted in a haemocytometer for
unstained (viable) and stained cells. The percentage of cell viability
was calculated as ((number of unstained cells)/(number of total
cells)) 100.
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Figure 1 Scheme of pSUPER.retro vectors. pS
 : original empty pSUPER.retro vector, with H1 promoter upstream ‘stuffer’ sequence; pS
H1: pSUPER.retro
vector in which shCOX-2 expression is controlled by H1 promoter; pS
COX 2: pSUPER.retro vector in which shCOX-2 expression is controlled by human
Cox-2 promoter; pS
TBE: pSUPER.retro vector in which shCOX-2 expression is controlled by a TBE-based promoter (carrying Tcf-binding elements).
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sCell invasion assay
Invasion assay was performed using Boyden chambers (New
Technologies Group, Milan, Italy) with 8-mm pore polycarbonate
membranes (New Technologies Group). Membranes were coated
with Matrigel (Sigma) at 40-fold dilution. Assay was performed
using fresh DMEM supplemented with 10% heat-inactivated
FCS as the chemoattractant agent. Forty-eight hours after InvColi
infection, viable HT-29 and HCA-7 cells were added into the upper
chamber at high density (3 10
5 cells) either in the absence or
presence of phorbol 12-myristate 13-acetate (PMA) 40nM stimula-
tion and then incubated for 24h at 371C. After incubation,
membranes were disassembled and non-invasive cells on the upper
surface of the membrane were wiped with a cotton swab.
The invasion index was determined by counting under light
microscopy the number per optical fields ( 200 magnification) of
cells that migrated to the lower side of each membrane, after fixing
and staining membranes with 2% Toluidine Blue.
Cytokines, chemokines, growth factors and PGE2 detection
Simultaneous detection of 29 extracellular factors released by
treated colon tissue samples was performed using Luminex
technology based on multiplexed bead immunoassay. Before assay,
cell media samples were concentrated 10 times using Microcon
spin devices (YM3, Millipore, Billerica, MA, USA) and subse-
quently re-suspended in Bio-Plex (Bio-Rad) assay buffer. The
levels of 27 cytokines, chemokines and growth factors (IL-1b,
IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70),
IL-13, IL-15, IL-17, PDGF-bb, bFGF, G-CSF, GM-CSF, VEGF, TNFa,
IFNg, IP-10, Eotaxin, MCP-1, MIP-1a, MIP-1b, Rantes) were
measured using the human ultrasensitive cytokine 27-plex antibody
bead kit (Bio-Rad). The IL-1a level was measured using Milliplex
Map kit (Millipore), whereas PGE2 levels were measured using the
Luminex Prostaglandin E2 Kit (Cayman Chemicals). The assays were
performed in 96-well filter plates, as per the manufacturers’
instructions. Concentration values were estimated using a standard
curve and a fifth-order polynomial equation and were expressed as
ngml
 1 or log (pgml
 1), after adjusting for the dilution factor
(Bio-Plex Manager software 5.0, Bio-Plex). The intra-assay CV,
including ultrafiltration and immunoassay, averaged 20%.
Statistical analysis
Data were expressed as mean±s.e.m. of three independent
experiments. Analysis of variance was used to assess the statistical
significance of the differences. Differences were considered
statistically significant at Po0.01.
RESULTS
Selective expression of siCOX-2 in colon cancer cells
In 2006, our group demonstrated that the COX-2 protein can be
efficiently and stably downregulated by a constitutive expression
of siRNA targeting COX-2 mRNA (siCOX-2) (Strillacci et al, 2006).
The HT-29 colon cancer cell line was transduced with a retro-
viral vector (pSUPER.retro) containing an expressing cassette
for shCOX-2 (siCOX-2 precursor molecule). In the pSUPER.
retro vector, the transcription of shRNA sequence is driven by the
human H1 promoter for RNA pol III (pS
H1). H1-driven transcrip-
tion leads to a constitutive expression of shRNA molecules in
almost every different type of transduced human cells. To improve
the selectivity of siCOX-2 expression, we modified the expression
cassette of shCOX-2 by substituting the promoter element.
In particular, we created the pS
COX 2 vector, in which the H1
promoter (pH1) was substituted with the human Cox-2 promoter
(pCOX-2), and the pS
TBE vector, in which pH1 was substituted with
a promoter containing TBEs (pTBEs), derived from TOPFLASH
plasmid (largely used for luciferase assays). In both cases, shCOX-
2 transcription is driven by RNA pol II that needs a polyA stop
signal (which has been introduced in pS-modified vectors,
downstream of shCOX-2 sequence) (Figure 1). Using this
approach, we made shCOX-2 expression dependent on COX-2
and on Wnt/b-catenin cellular pathways, both highly activated in
CRC cells. In fact, it is well known that CRC cells overexpress the
COX-2 protein and this phenomenon depends on transcriptional
(Yamamoto et al, 1995; Duque et al, 2005; Wu et al, 2005; Kaidi
et al, 2006) and post-transcriptional regulation (Dixon et al, 2001;
Strillacci et al, 2009). On the other hand, b-catenin is preferentially
localised at the plasma membrane of normal colonocytes and
promotes cellular adhesion, linking E-cadherin to the cytoskeleton.
In CRC cells, as a consequence of mutations (Morin et al, 1997)
and/or other cellular stimuli (Brabletz et al, 2001; Castellone et al,
2005), b-catenin frequently translocates in the nucleus and
promotes the transcription of genes involved in cell proliferation,
migration, survival, angiogenesis and stemness (Brabletz et al,
2005). In the nucleus, b-catenin associates with the transcriptional
complex Tcf-4/Lef-1 (T-cell factor 4/lymphoid enhancer factor 1)
and binds DNA on TBE promoter sequences. Figure 2 shows
the expression levels of siCOX-2 in different human cell
lines transiently transfected with pS
  (empty vector, negative
control), pS
H1,p S
COX 2 and pS
TBE vectors. By transfecting CRC
cell lines with pS
COX 2 and pS
TBE vectors, it is possible to gain a
highly selective expression of siCOX-2. In fact, in HT-29 and
HCA-7 colon cancer cells, siCOX-2 expression driven by pCOX-2
and pTBE promoters resulted to be even higher than siCOX-2
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Figure 2 Selective expression of siCOX-2 in CRC cells. Six human cell lines were transfected with pS vectors, and siCOX-2 expression was evaluated by
real-time PCR (48h after transfection) and normalised against U6 RNA expression. For each cell line, relative expression of siCOX-2 refers to
pS
H1-transfected sample. Data represent mean±s.e.m. of three independent experiments. *Po0.01.
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sexpression driven by the pH1 promoter. As expected, in the HCT-
116 colon cancer cell line (that does not express the COX-2
protein), we did not record a significant expression of siCOX-2
driven by pCOX-2, whereas siCOX-2 expression driven by pTBE
was slightly higher than pH1. On the contrary, in NCM-460
(normal epithelial colon cells), HeLa (human cervix carcinoma
cells) and HEK-293 (human transformed kidney cell line) cells,
siCOX-2 expression driven by pCOX-2 and pTBE resulted to be
very low, if compared with pH1-driven siCOX-2 expression.
InvColi infection induces COX-2 silencing in CRC cell lines
and significantly reduces PGE2 synthesis and release
In 1998, Grillot-Courvalin et al (1998) showed that an engineered
E. coli strain, expressing heterologous Inv and HlyA genes, was
able to infect/invade mammalian cells and release DNA into host
cells. On the basis of this approach, we developed a strategy to
induce an RNAi-mediated COX-2 silencing in HT-29 and HCA-7
colon cancer cell lines. Bacterial LPS is known to induce COX-2
expression in human cells (Hla and Neilson, 1992). Thus, we first
tested bacterial infection on CRC cells using InvColi-pS
  (see the
‘Materials and Methods’ section for details on InvColi-pS strains)
at different MOIs. At an MOI value of 1:1000, we did not record
any significant COX-2 overexpression due to the presence of
bacterial LPS (data not shown). Second, we provided evidence that
InvColi strains created in our laboratory were able to infect and
invade human CRC cells at an MOI of 1:1000. To this purpose, we
used the InvColi-pS
TBE.p S
TBE vector, as the other pS vectors
described above, carries a GFP reporter gene. Both HT-29 and
HCA-7 cells infected with InvColi-pS
TBE started to express the GFP
protein 48h after infection (Figure 3A and B). An B90% infection/
invasion efficiency was estimated on both cell lines. Moreover,
soon after infection, it was possible to detect inside the cells, by
PCR analysis, the presence of Inv-HlyA and pTBE sequences,
carried by the pGB2-O-inv-hly plasmid and pS
TBE vector,
respectively (Figure 3C).
Using the InvColi-mediated RNAi approach, we achieved a high
COX-2 silencing in CRC cell lines. In fact, 48h after infection with
invasive InvColi strains transformedw i t hs h C O X - 2 - e x p r e s s i n gv e c t o r s
(InvColi-pS
H1,I n v C o l i - p S
COX 2 and InvColi-pS
TBE), we started to
observe a significant reduction in COX-2 protein and mRNA levels in
HT-29 and HCA-7 cells (Figure 3D and E). Interestingly, COX-2
silencing with InvColi-pS
TBE was more effective than the silencing
obtained with InvColi-pS
  (negative control) or InvColi-pS
H1/COX 2
bacteria. Most likely, the stronger COX-2 silencing obtained with
InvColi-pS
TBE was dependent on a higher siCOX-2 expression,
as detected in both HT-29 and HCA-7 cells (Figure 3D and E).
Silencing results were highly comparable with those obtained after
transfection of pS vectors into HT-29 and HCA-7 cells using the
Lipofectamine 2000 Transfection Reagent (Invitrogen) (see Supple-
mentary Material). We recorded a significant COX-2 protein
silencing up to 5 days after InvColi-pS infection (data not shown).
Very interestingly, prolonged COX-2 inhibition was associated with a
strong impairment of PGE2 production (Figure 4) and, as previously
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sdemonstrated with western blot analysis, the strongest inhibitory effect
was obtained after InvColi-pS
TBE infection.
We also evaluated whether COX-2 silencing induced by InvColi-
RNAi might have been the result of an off-target effect depending
on interferon system activation (in particular, the Jak-STAT
pathway) (Sledz et al, 2003). Western blot analysis of phospho-
STAT-1(Tyr701) (active form) levels, normalised against p85/p91
STAT-1 total protein levels, showed that the interferon system
response was triggered only at high MOI values (1:100), whereas
infection at MOI 1:1000 did not have any effect on STAT-1
phosphorylation (data not shown).
COX-2 silencing mediated by RNAi after InvColi
infection impairs proliferation, survival and
invasiveness of CRC cells
As we have demonstrated an effective COX-2 silencing in CRC cells
mediated by InvColi-pS strains, we have further investigated
the phenotype of infected cells. Figure 5 shows data regarding
proliferation and viability of COX-2-silenced HT-29 (Figure 5A
and B) and HCA-7 (Figure 5C and D) cells and results were in high
accordance in both cell lines. InvColi-pS
COX 2 and, in particular,
InvColi-pS
TBE infection induced a significant reduction in CRC cell
proliferation and viability, despite InvColi-pS
H1 infection that led
only to a slight reduction. As COX-2 overexpression is involved
in the malignant behaviour and invasiveness of CRC cells, we
analysed the effect of the specific COX-2 silencing mediated by
InvColi-RNAi in HT-29 and HCA-7 cells by performing a cell
invasion assay, 48h after InvColi infection. The invasion index
of both cell lines was significantly reduced after COX-2 silen-
cing (Figure 6A and B). Although in HT-29 we did not record
any significant difference between the effectiveness of
InvColi-pS
H1, InvColi-pS
COX 2 and InvColi-pS
TBE, in HCA-7
InvColi-pS
COX 2 and InvColi-pS
TBE, infection induced a stronger
reduction in the invasion index with respect to InvColi-pS
H1. The
impairment of the invasive behaviour of CRC cells due to RNAi-
mediated COX-2 silencing was further confirmed after stimulation
with PMA, which is known to induce COX-2 expression (Crofford
et al, 1994) and promote cancer cell invasion (Han et al, 2000)
(Figure 6A and B). These findings are in line with our pre-
vious work in which we demonstrated that a stable COX-2
downregulation in HT-29 cells, mediated by pH1-driven shCOX-2
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sexpression, induces a significant impairment of malignant
behaviour of HT-29 cells (Strillacci et al, 2006).
CRC cell survival after bacterial infection depends
on COX-2 overexpression
It is known that COX-2 has a key role in colon cancer progression
and survival of colon cancer cells. Recently, we demonstrated that
a COX-2/CA-IX (carbonic anhydrase IX) interplay controls CRC
cell survival under hypoxic conditions (Sansone et al, 2009).
Therefore, we aimed to demonstrate that COX-2 overexpression
is also required for the survival of CRC cells after infection of
invasive E. coli strains. As we have previously demonstrated
(Strillacci et al, 2006), COX-2 stable silencing mediated by
retroviral transduction did not affect proliferation and survival
of HT-29 cells. In fact, we did not record any difference in the
proliferation rate between HT-29
pS( ) (negative control) and HT-
29
pS(shCOX 2) (in which COX-2 is stably downregulated). However,
after a prolonged infection with invasive InvColi-pS
  (MOI 1:100,
6h incubation, day 0), we observed a significant difference in cell
proliferation and cell viability between HT-29
pS( ) and HT-
29
pS(shCOX 2) cells (Figure 7A and B). At MOI 1:100, bacterial
infection rapidly induced COX-2 overexpression in HT-29
pS( )
cells (days 1–4), most probably due to the higher presence of LPS
(Hla and Neilson, 1992), but we did not observe this phenomenon
in HT-29
pS(shCOX 2) cells (Figure 7C). The lack of high COX-2
protein levels in infected HT-29
pS(shCOX 2) cells led to a significant
reduction in cell proliferation and viability. To further confirm the
important role of the COX-2 protein in CRC cell survival, we
performed InvColi-pS infection on HCT-116 cells, a CRC cell line
not expressing the COX-2 protein. As expected, COX-2 protein and
mRNA levels were not detectable in HCT-116 cells after 6h
infection with InvColi-pS strains at MOI 1:100 (data not shown).
Importantly, the absence of COX-2 overexpression in infected
HCT-116 cells led to a dramatic decrease in cell proliferation and
viability (Figure 8A and B), as for HT-29
pS(shCOX 2) cells. More-
over, infected HCT-116 cells showed a reduced ability to invade
Matrigel-coated filters (Figure 8C).
COX-2 silencing mediated by InvColi strains in colon
tissue samples
We evaluated the efficacy of COX-2 silencing ex vivo using
InvColi-based RNAi on fresh colon tissue samples. To this
purpose, samples were collected from patients affected by acute
ulcerative colitis, supposed to be characterised by COX-2 protein
expression. Levels of COX-2 protein, COX-2 mRNA and siCOX-2
were analysed 48h after infection of biopsies with InvColi-pS
strains (MOI 1:1000, 6h incubation). As shown in Figure 9A,
negative controls (untreated sample and sample infected with
InvColi-pS
 ) were characterised by COX-2 expression, as ex-
pected. A significant COX-2 protein/mRNA reduction and siCOX-2
expression were recorded in samples infected with InvColi-pS
H1,
InvColi-pS
COX2 and InvColi-pS
TBE, compared with negative con-
trols. Very importantly, InvColi-pS
TBE infection had the strongest
effect, further confirming the in vitro data (see above). We also
evaluated the effect of COX-2 silencing in colon tissues by
analysing the levels of PGE2, cytokines, chemokines and growth
factors present in the conditioned media 48h after infection. For
this analysis, only tissue samples infected with InvColi-pS
 
(negative control) and InvColi-pS
TBE (which showed the most
effective COX-2 silencing) were taken into consideration and all
data collected are shown in Figure 9B and C. As expected, COX-2
protein silencing mediated by InvColi-pS
TBE led to a strong
decrease in PGE2 secretion. Moreover, in media derived from
InvColi-pS
TBE-infected cells, we found a significant decrease in
IL-1a, IL-1b, IL-6, IL-8, IL-12(p70), IL-17, PDGF-bb, bFGF, VEGF,
IP-10, MCP-1 and MIP-1b, whereas we observed a marked increase
in IL-1ra, IL-2, IL-15, TNFa and Eotaxin. Levels of IL-4, IL-5 and
IL-10 were not detectable. Interestingly, COX-2 silencing led to a
strong decrease in the secretion of pro-inflammatory cytokines
such as IL-1a/b (Liu et al, 2003; Matsuo et al, 2009), IL-6 (Becker
et al, 2005) or IL-8 (Brew et al, 2000), and that of pro-angiogenic
growth factors such as PDGF-bb (Hsu et al, 1995), bFGF (Galzie
et al, 1997) and VEGF (Takahashi et al, 1995). Furthermore, there
was an increased secretion of some anti-inflammatory cytokines,
such as IL-1ra (Konishi et al, 2005), and of cytokines with anti-
tumour effect, such as IL-2 (Caporale et al, 2007) and IL-15 (Zhang
et al, 2009). Similarly, TNFa increased secretion might exert an
anti-tumour effect on colon cells, even if its role in CRC is still
controversial (Koshiji et al, 1998; Popivanova et al, 2008). Thus, by
a global analysis of ex vivo data, it results clear that InvColi-
mediated RNAi induced COX-2 silencing and exerted an anti-
inflammatory and anti-tumour effect on colon cells.
DISCUSSION
Over the last decades, a large body of experimental evidence has
ascribed to the COX-2 enzyme an important role in colorectal
tumourigenesis. Cyclooxygenase-2 is overexpressed in colon
tumour tissues (Eberhart et al, 1994; Sano et al, 1995) and
contributes to CRC progression and malignancy through mechan-
isms that act on cell proliferation/invasion (Yamauchi et al, 2002;
Strillacci et al, 2006), apoptosis inhibition (Tsujii and DuBois,
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s1995) and tumour angiogenesis (Spisni and Tomasi, 1997; In ˜iguez
et al, 2003). It has been demonstrated that the chronic use of
NSAIDs, inhibitors of COX activity, reduces CRC incidence in
treated patients (Phillips et al, 2002; Thun et al, 2002; Higuchi et al,
2003; Sandler et al, 2003). Among these, ‘coxibs’ have been
developed and marketed for the selective block of COX-2 activity.
Celecoxib, rofecoxib, lumiracoxib and etoricoxib have been em-
ployed in many clinical trials to test their safety associated with the
chronic use, but data collected are debated. The high incidence of
cardiovascular adverse events is associated with the chronic use of
coxibs (Bresalier et al, 2005; Solomon et al, 2005) and it seems clear
that other pharmacological strategies, based on COX-2 inhibition,
are required for the prevention and/or treatment of CRC.
Cyclooxygenase can be efficiently and selectively inhibited by
RNAi techniques, either in a transient or a long-lasting manner
(Strillacci et al, 2006). RNAi has become the first choice for gene
silencing in vitro despite many disadvantages of RNAi approaches
in vivo. RNAi-based silencing molecules can be delivered in vivo
by intravenous injections or expressed by the use of viral-based
systems. However, poor pharmacodynamics and/or heavy side
effects reduce their use and effectiveness in vivo.
Hereby, we provide data supporting an alternative approach to
target CRC cells and induce a highly selective COX-2 silencing,
mediated by RNAi, both in vitro and ex vivo.I np a r t i c u l a r ,
we engineered invasive E. coli strains (InvColi) carrying siCOX-2
(siRNA sequences targeting COX-2 mRNA)-expressing vectors
(pSUPER.retro, pS). These bacteria were able to infect/invade
CRC cells and release their DNA contents, leading to a strong
COX-2 silencing.
First, we modified the pS vector to gain a tumour-specific
shCOX-2 expression. The basic pS vector allows a constitutive
expression of shCOX-2 (siCOX-2 precursor) in almost every
human cell line as shCOX-2 transcription is driven by the H1
promoter for RNA pol III (pS
H1). Thus, we modified this
expression cassette by substituting the H1 promoter with the
human Cox-2 promoter (in pS
COX 2) or with a promoter sequence
containing TBEs (in pS
TBE), which represent the downstream
target sequences on human genomic DNA of the Wnt/b-catenin-
activated pathway. It is well known that Cox-2 promoter activity is
highly stimulated in CRC cells. Many cellular stimuli contribute to
activate this phenomenon that leads to COX-2 overexpression
(Yamamoto et al, 1995; Dixon et al, 2001; Duque et al, 2005;
Wu et al, 2005; Kaidi et al, 2006; Strillacci et al, 2009). The Wnt/b-
catenin pathway is highly activated in CRC cells and such an
activation is caused by cellular stimuli or by mutation of proteins
involved in the pathway, such as APC or b-catenin itself
(Morin et al, 1997; Brabletz et al, 2001, 2005; Castellone et al,
2005). By the use of pS
COX 2 and pS
TBE vectors, we demonstrated
that siCOX-2 can be expressed in a more effective and selective
manner in CRC cells. Under Cox-2 or a TBE-based promoter
control, siCOX-2 expression in CRC cell lines (HT-29 and HCA-7)
was higher, if compared with H1-driven expression. On the
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Figure 7 HT-29 cell survival after bacterial infection depends on COX-2 overexpression. (A) Cell number, (B) cell viability and (C) COX-2 protein
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pS(shCOX 2) cells infected with InvColi-pS
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See the ‘Materials and Methods’ section for details on cell lines. (E) HT-29
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( ) negative control vector; (’) HT-29
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cells, transduced with pS
(shCOX 2) vector and stably silenced for COX-2 protein; (m): HT-29
pS( ) INF cells, transduced with pS
( ) negative control vector
and infected with InvColi-pS
 ;( K): HT-29
pS(shCOX 2) INF cells, transduced with pS
(shCOX 2) vector and infected with InvColi-pS
 . Viability was detected
using the Trypan Blue exclusion assay and quantified as ((number of unstained cells)/(number of total cells)) 100. COX-2 protein expression
was evaluated by western blot and normalised against b-actin protein. COX-2 relative expression refers to not infected HT-29
pS( ) sample, day 0. Data
represent mean±s.e.m. of three independent experiments. *Po0.01.
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scontrary, siCOX-2 resulted in very low expression in normal colon
epithelial cells (NCM-460) or in other human tumour cell lines
(such as HeLa and HEK-293).
Second, we demonstrated that shCOX-2-expressing vectors
(pS
H1,p S
COX 2 and pS
TBE) can be efficiently delivered into
HT-29 and HCA-7 CRC cell lines after infection with InvColi
strains (MOI 1:1000), thus promoting a strong COX-2 down-
regulation (both at mRNA and protein levels) mediated by RNAi
and a prolonged reduction in PGE2 levels. Most likely, this
phenomenon led to the significant reduction in cell proliferation,
viability and invasiveness observed in infected CRC cells. Very
interestingly, shCOX-2 expression driven by the TBE promoter
induced the highest COX-2 silencing, which resulted in a strong
impairment of the tumour-associated phenotype. It seems clear
that, by using the pS
TBE vector, it is possible to gain both efficacy
and specificity for COX-2 silencing in CRC cells.
We used our model to further demonstrate the pivotal role of
COX-2 overexpression in CRC cell survival. By infecting HT-29
cells stably silenced for COX-2 (HT-29
pS(shCOX 2), previously
developed in our laboratory) with InvColi-pS
  at a higher MOI
value (1:100), we observed a significant reduction in cell
proliferation and survival, with respect to the negative control
(HT-29
pS( ) cells). As it is well known that bacterial LPS induces
COX-2 expression in human cells and, as we show herein, InvColi-
pS
  infection at an MOI 1:100 induces COX-2 overexpression in
CRC cells, our hypothesis is that the survival of CRC cells after
bacterial infection could be strictly dependent on COX-2 induc-
tion. This observation was further confirmed in HCT-116 cells, a
CRC cell line unable to express COX-2. In fact, the lack of COX-2
protein induction after InvColi-pS strain infection led to a
significant impairment of cell proliferation, viability and invasive-
ness of HCT-116 cells. We did not record differences between the
four InvColi-pS strains used for HCT-116 infection. InvColi-pS
 
infection had the same effect of InvColi-pS
H1, InvColi-pS
COX2 and
InvColi-pS
TBE infection. Thus, as for HT-29
pS(shCOX 2), the
biological effect on HCT-116 cells was dependent on InvColi-pS
infection per se, rather than on siCOX-2 expression. On the other
hand, the global effect of InvColi-pS infection on CRC cell lines
expressing COX-2 (HCA-7 and HT-29) is the result of COX-2
silencing mediated by RNAi, PGE2 levels reduction and cellular
stress induced by bacteria infection.
Finally, in the light of a possible in vivo application, we tested
ex vivo the efficacy of selective COX-2 silencing mediated by InvColi-
based RNAi. Colon tissue samples, derived from patients affected by
acute ulcerative colitis and expressing COX-2 protein, were infected
with InvColi-pS strains and this resulted in a strong COX-2
inhibition at both mRNA and protein levels, especially after infection
with InvColi-pS
TBE. Cyclooxygenase-2 silencing was associated
with a significant reduction in PGE2 and pro-inflammatory/
pro-angiogenic factors (cytokines, growth factors) released by colon
InvColi-pS
TBE-infected cells. Moreover, we observed an increased
production of factors with anti-inflammatory and anti-tumour effects.
In conclusion, we developed an RNAi-based strategy to
efficiently and specifically silence the COX-2 protein in CRC cells,
in vitro and ex vivo. Cyclooxygenase-2 downregulation, depending
on InvColi-pS infection, induced a strong impairment of both
proliferative and invasive behaviour of CRC cells in vitro and a
significant anti-inflammatory and anti-tumour effect ex vivo.
Taken together, our data demonstrate the feasibility of an RNAi-
based/InvColi-driven approach for COX-2 silencing aimed at the
prevention of CRC or the treatment of other inflammatory bowel
diseases characterised by COX-2 overexpression. Using engineered
E. coli strains or other non-pathogenic bacteria, siCOX-2 silencing
could be locally delivered and expressed in colorectal tissues, thus
promoting a blockade of COX-2 activity, supposedly deprived of
systemic side effects.
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Figure 9 InvColi-pS strains infect colon tissue samples and induce high COX-2 silencing associated with anti-inflammatory and anti-angiogenic effects.
(A) COX-2 protein, COX-2 mRNA and siCOX-2 levels were analysed in colon tissue samples by western blot and real-time PCR, 48h after InvColi strain
infection. COX-2 protein, COX-2 mRNA and siCOX-2 expression was normalised against b-actin protein, GUSB (b-glucuronidase) mRNA and U6 RNA
levels, respectively. Relative expression of COX-2 protein and COX-2 mRNA refers to not infected samples (negative control, NC); relative expression of
siCOX-2 refers to InvColi-pS
TBE infected samples. Data represent mean±s.e.m. of three independent experiments. *Po0.01. (B) Levels of PGE2,
(C) cytokines, chemokines and growth factors were quantified in InvColi-pS
 - and InvColi-pS
TBE-infected colon tissues conditioned media, 48h after
infection, by a Luminex-based multiplexed bead immunoassay. Concentration values are expressed as log(pgml
 1) and represent mean±CV of three
independent measurements, normalised considering the total protein amount extracted from each tissue sample. *Po0.01.
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